1. Home
  2. ONTO vs BLCO Comparison

ONTO vs BLCO Comparison

Compare ONTO & BLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ONTO
  • BLCO
  • Stock Information
  • Founded
  • ONTO 1940
  • BLCO 1853
  • Country
  • ONTO United States
  • BLCO Canada
  • Employees
  • ONTO N/A
  • BLCO N/A
  • Industry
  • ONTO Industrial Machinery/Components
  • BLCO Ophthalmic Goods
  • Sector
  • ONTO Industrials
  • BLCO Health Care
  • Exchange
  • ONTO Nasdaq
  • BLCO Nasdaq
  • Market Cap
  • ONTO 6.0B
  • BLCO 5.2B
  • IPO Year
  • ONTO N/A
  • BLCO 2022
  • Fundamental
  • Price
  • ONTO $122.72
  • BLCO $14.31
  • Analyst Decision
  • ONTO Strong Buy
  • BLCO Hold
  • Analyst Count
  • ONTO 7
  • BLCO 12
  • Target Price
  • ONTO $150.00
  • BLCO $15.91
  • AVG Volume (30 Days)
  • ONTO 1.9M
  • BLCO 569.2K
  • Earning Date
  • ONTO 10-30-2025
  • BLCO 10-29-2025
  • Dividend Yield
  • ONTO N/A
  • BLCO N/A
  • EPS Growth
  • ONTO 20.58
  • BLCO N/A
  • EPS
  • ONTO 4.04
  • BLCO N/A
  • Revenue
  • ONTO $1,036,353,000.00
  • BLCO $4,891,000,000.00
  • Revenue This Year
  • ONTO $2.90
  • BLCO $8.29
  • Revenue Next Year
  • ONTO $8.96
  • BLCO $5.82
  • P/E Ratio
  • ONTO $30.01
  • BLCO N/A
  • Revenue Growth
  • ONTO 15.51
  • BLCO 8.81
  • 52 Week Low
  • ONTO $85.88
  • BLCO $10.45
  • 52 Week High
  • ONTO $228.42
  • BLCO $21.69
  • Technical
  • Relative Strength Index (RSI)
  • ONTO 46.88
  • BLCO 42.41
  • Support Level
  • ONTO $134.00
  • BLCO $14.40
  • Resistance Level
  • ONTO $150.21
  • BLCO $15.25
  • Average True Range (ATR)
  • ONTO 6.91
  • BLCO 0.46
  • MACD
  • ONTO -1.09
  • BLCO -0.10
  • Stochastic Oscillator
  • ONTO 0.26
  • BLCO 26.41

About ONTO Onto Innovation Inc.

Onto Innovation Inc is engaged in the design, development, manufacture, and support of high-performance control metrology, defect inspection, lithography, and data analysis systems used by microelectronics device manufacturers. The Company and its subsidiaries currently operate in a single operating segment. The company mainly operates in the United States, Southeast Asia, China, Japan, and Europe, with Taiwan and South Korea the sources of total revenue.

About BLCO Bausch + Lomb Corporation

Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.

Share on Social Networks: